fbpx
Contact Us

InVivo Biosystems Blog

Category: Drug Discovery

Leaky gut assays feature image

Leaky Gut Assays in Animal Models

By:
Alexandra Narin ,
Chris Hopkins ,
Inflammation in your intestine is detrimental to overall health, and can create many complications. So how is this phenomenon researched?
READ MORE
No animals, new drugs, no problem

New drugs, No Animals, No Problem. The FDA announced legislative changes – drugs are no longer required to be tested in animals before moving to human trials. What does that mean?

By:
Alexandra Narin ,
The FDA announced animal testing no longer necessary for drug discovery. In this article we discuss the implications for USA’s drug pipeline.
READ MORE
WHAM with CRISPR - re-imaging how rare disease therapeutics are developed

Whole-gene Humanized Animal Models (WHAM) with CRISPR – Re-imagining how Rare Disease therapeutics are developed

By:
Chris Hopkins ,
Alexandra Narin ,
Traditional modeling of patient variants in vivo has two limitations which can be overcome utilizing InVivo Biosystems’ patented WHAM-method.
READ MORE
customer story: zebrafish CRO feature image

Using Zebrafish CRO to Accelerate Grant Application Process

By:
Alexandra Narin ,
Dr Quintana chose to leverage InVivo Biosystems’ fully validated custom injection mixes to create point mutations that target the protein HFC1 in zebrafish
READ MORE
WHAM - humanized animal models for drug discovery

WHAMyness – How Gene-Humanized Animals Can Dramatically Improve Drug Discovery

By:
Chris Hopkins ,
Alexandra Narin ,
Current in vivo platforms are limited in their ability to identify drug candidates – Whole-gene Humanized Animal Models can help.
READ MORE

America is finally investing in Biotechnology & Biomanufacturing in a Big Way

By:
Alexandra Narin ,
In this article we discuss what President Biden’s New Executive Order means for America’s place in the biotech and biomanufacturing fields.
READ MORE

The Path to Affordable Therapeutics in Rare Disease – Tackling Congenital Disorder of Glycosylation in the PMM2 gene [Customer Story].

By:
Hannah Huston ,
Alexandra Narin ,
Chris Hopkins ,
READ MORE

[Patent Announcement] InVivo Biosystems has officially been issued a patent on WHAM-humanization in the nematode, C. elegans

By:
Alexandra Narin ,
We are excited to announce that the USPTO has issued a patent titled, ‘Transgenic animal phenotyping platform and uses thereof’ to InVivo Biosystems.
READ MORE

Looking at Gene Paralogs across both zebrafish and C. elegans Model Organisms [Customer Story]

By:
Alexandra Narin ,
Drs Pruyne & Almack leveraged InVivo Biosystems’ Custom Injection Mix to design and create a novel zebrafish line.
READ MORE

Part Two: Is Drug Repurposing the New Model for Drug Discovery?

By:
Astha Nimavat ,
READ MORE

Part One: An Overview of Drug Repurposing

By:
Astha Nimavat ,
READ MORE

Chemicals Models of Parkinson’s Disease in Larval Zebrafish

By:
Laura Taggart-Murphy ,
Alexandra Narin ,
READ MORE

Poking its way into Western Medicine: How Acupuncture Could Help Ease Chronic Pain

By:
Alexandra Narin ,
READ MORE

A Natural Fit – Using Zebrafish to Evaluate Natural Compounds for Anti-Inflammatory Properties

By:
Laura Taggart-Murphy ,
Alexandra Narin ,
READ MORE

Quick Guide to Natural Products: What They are and How They Impact You

By:
Alexandra Narin ,
Summary: This Earth Month we at InVivo Biosystems are thinking about how we utilize Earth’s resources in biomedicine – from animal systems that enable us
READ MORE
microbiome models feature image

Models to Research Microbiome

By:
Alexandra Narin ,
Chris Hopkins ,
In this article, we will discuss the commonly used model organisms for microbiome research, and what insights they can provide.
READ MORE
zfish as drug discovery tool feature image

Lost and Found: Zebrafish as a Drug Discovery Tool

By:
Alexandra Narin ,
Summary Zebrafish models largely began as a way to research developmental biology, however, their potential to be a preclinical model of human disease quickly became
READ MORE

Neuroscience Models: Transgenic Mice, Zebrafish, C. Elegans – And Jellyfish?

By:
Alexandra Narin ,
READ MORE

From ED to AD: a drug repurposing success? How a performance-enhancing drug is giving insight into dementia

By:
Alexandra Narin ,
Recently, researchers at Cleveland Clinic’s Genomic Medicine Institute published an article in Nature Aging which has caused quite a stir in the medical community and
READ MORE

The In (vitro, vivo, silico)s and Outs of Research

By:
Alexandra Narin ,
Experiments fall into three categories – in vivo, in vitro, and in silico studies, and all of them have a different, but important role in
READ MORE

The Discrepancy Between Sexes: Clinical Models & Clinical Trials

By:
Alexandra Narin ,
Pharmaceutical drugs go through a rigorous process that tests their safety and efficacy before gaining FDA approval and being put on the commercial market. Traditionally,
READ MORE

A Closer Look at Nutraceutical Regulations: How Does the USA Compare?

By:
Alexandra Narin ,
In this article we will explore how the nutraceutical regulations compare in the USA and abroad, asking how they are defined in each country, what
READ MORE

Recent Nutraceutical Research

By:
Alexandra Narin ,
We’ve rounded up some of the recent publications that we’ve been enjoying – click their links below to see what’s new in this space!
READ MORE

Testing the Neuroprotective Effect of a Lead Compound Using C. elegans for Fast and Cost-Effective Answers [Customer Story]

By:
Hannah Huston ,
Alexandra Narin ,
READ MORE

FDA versus FTC Approval – What is the Difference?

By:
Alexandra Narin ,
In this article we aim to clarify the intent behind these therapies and what their labelling means by asking: Why aren’t nutraceutical products FDA approved?
READ MORE

HIV, COVID-19, Alzheimer’s: The Impact of The FDA’s Expedited Programs and What’s Next

By:
Alexandra Narin ,
The FDA’s emergency use authorization (EUA) of the COVID-19 vaccines has brought the approval process of vaccines and drugs into public consciousness, however, the FDA’s
READ MORE

How Can a Drug Get to Market Faster? Explaining the FDA’s Expedited Drug Tracks

By:
Alexandra Narin ,
Getting a drug to market is notoriously difficult, taking 7-10 years and costing hundreds of millions of dollars. This, coupled with the Covid-19 pandemic’s impact
READ MORE

New Alzheimer’s Drug: Helpful or Just Expedient?

By:
Alexandra Narin ,
Aducanumab has been plagued with controversy since it was announced. We take a look to see if it is helpful, or just expedient.
READ MORE

Rising Healthcare Costs? Non-Mammalian Models To The Rescue

By:
Alexandra Narin ,
READ MORE

The Application of Hypersensitivity Assays to the Discovery of Therapeutics

By:
Chris Hopkins ,
Using Humanization we can take advantage of the ancient biology between humans and other organisms to create stand-ins – patient avatars – for drug screening
READ MORE

Let’s Fail Faster: Why Scientific Failures Should be Accepted as Progress

By:
Alexandra Narin ,
In the scientific community there is an emphasis on positive results: getting published, having a drug be approved, etc. However, crucial learning happens when experiments
READ MORE

The DrugAge Database: Showcasing C. Elegans In Longevity Research

By:
Alexandra Narin ,
Trisha Brock ,
READ MORE

Drug Repurposing for Neurological Disorders

By:
Alexandra Narin ,
Neurological disorders are extremely widespread, affecting over 1 billion people worldwide, and have debilitating effects, impacting the brain, spinal cord, cranial nerves, and peripheral nerves.
READ MORE

Whole Gene Humanization for Personalized Medicine Applications

By:
Chris Hopkins ,
We have found whole gene humanization can create a platform for highly translatable results in a model organism. Currently there is a big need for
READ MORE

How to Design a Good Phenotype Based Drug Discovery Program, and Why It Matters.

By:
Kathryn McCormick ,
With the advent of the molecular biology revolution and the human genome project in the 1990s there was a historic shift toward target-based drug
READ MORE

Understanding GPCRs Using Humanized C. elegans

By:
InVivo Biosystems ,
Our CSO, Dr. Chris Hopkins presented at DR. GPCR SUMMIT 2020 on why C. elegans is an ideal model to study the underlying principles of GPCRs.
READ MORE

Longevity Studies Using C. elegans to Identify Potential Anti-Aging Compounds [Customer Story]

By:
InVivo Biosystems ,
Dr. Vollmer shares his experience working with us and how the Longevity Platform delivers the results he needs within his timeline and budget.
READ MORE

Seventeen Minutes of Science: Viral Gene Therapies and Their Potential Use Against COVID-19

By:
InVivo Biosystems ,
Tune in weekly to our virtual series “Seventeen Minutes of Science” every Tuesday at 11am PST / 2pm ET where we go live on Facebook
READ MORE

Bacteria, Protozoa And Nematodes, Oh My!: Seeking New Drugs Against COVID-19

By:
Janis Weeks, Ph.D. ,
READ MORE

Seventeen Minutes of Science: Spreading out from Kendall (Episode 6)

By:
Hannah Huston ,
READ MORE

[New Webinar] A Shortcut to Understanding Longevity

By:
Hannah Huston ,
READ MORE

Zebrafish and C. elegans in ALS: tightening the bench-to-clinic gap

By:
InVivo Biosystems ,
While advances in molecular imaging, high-throughput screening, genomics and techniques like CRISPR-Cas9 gene editing have dramatically enhanced our understanding of the human body and disease,
READ MORE

wMicroTracker Applications: Drug Screening

By:
Yoanne Clovis, Ph.D. ,
The wMicroTracker is a great product to add to your drug screening toolkit. Check out the application sheet below to see how easy it is
READ MORE

Worms, Flies or Fish? A Comparison of Common Model Organisms — Part 2: Models for human diseases

By:
Yoanne Clovis, Ph.D. ,
Non-mammalian model organisms are typically used in early research to deliver fast answers to a discovery problem. The most popular model organisms in biological and
READ MORE

Worms, Flies or Fish? A Comparison of Common Model Organisms – Part 1: Models for Biomedical Research

By:
Yoanne Clovis, Ph.D. ,
Non-mammalian model organisms are typically used in early research to deliver fast answers to a discovery problem. The most popular model organisms in biological and
READ MORE

Are worms the future of drug development?

By:
InVivo Biosystems ,
NemaMetrix’s ScreenChip collects live-animal, high-throughput C. elegans electropharyngeograms (EPGs), which are an indication of overall organism health for drug development. Read the blog post on BioCoder
READ MORE
Load More
  • Categories

    • Connect with us

    Facebook Twitter Linkedin
    stay updated..

    The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
    giving you all of the latest company updates, industry news, and more.

    Sign Up

    An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.

    Quick Links
    Contact Us

    Headquarters: 1505 Westec Drive, Eugene, OR 97402

    1.844.663.8749.

    Facebook Twitter Linkedin
    Copyright © 2022 InVivo Biosystems. All rights reserved.
    Facebook Twitter Linkedin